LDH5 overexpression is associated with poor survival in patients with solid tumors: A meta-analysis

Tumor Biology

Volumn 35, Issue 7, 2014, Pages 6973-6981

  Yao, YanHong ^a   Wang, HaiTao ^a   Li, BaoGuo ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Cancer; Disease recurrence progression free survival; Lactate dehydrogenase 5; Meta analysis; Overall survival

Indexed keywords

LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE 5; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; HUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PUBLISHING; RECURRENCE FREE SURVIVAL; SOLID TUMOR; SYSTEMATIC REVIEW;

DISEASE-FREE SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; ISOENZYMES; L-LACTATE DEHYDROGENASE; NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84904962375     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1903-3     Document Type: Article

References (47)

1. Kitamura T, Taketo MM. Keeping out the bad guys: gateway to cellular target therapy. Cancer Res. 2007;67:10099-102. (Pubitemid 350070778)
2. Michaylira CZ, Nakagawa H. Hypoxic microenvironment as a cradle for melanoma development and progression. Cancer Biol Ther. 2006;5:476-9. (Pubitemid 43765279)
3. Giatromanolaki A, Sivridis E, Kouskoukis C, Gatter KC, Harris AL, Koukourakis MI. Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res. 2003;13:493-501. (Pubitemid 37266952)
4. Firth JD, Ebert BL, Ratcliffe PJ. Hypoxic regulation of lactate dehydrogenase a. Interaction between hypoxia-inducible factor 1 and cAMP response elements. J Biol Chem. 1995;270:21021-7.
5. Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P, et al. Hypoxia response elements in the aldolase a, enolase 1, and lactate dehydrogenase a gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem. 1996;271:32529-37.
6. WARBURG O. On the origin of cancer cells. Science. 1956;123:309-14.
7. WARBURG O. On respiratory impairment in cancer cells. Science. 1956;124:269-70.
8. Dang CV. Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. Cancer Res. 2010;70:859-62.
9. Grimm M, Alexander D, Munz A, Hoffmann J, Reinert S. Increased LDH5 expression is associated with lymph node metastasis and outcome in oral squamous cell carcinoma. Clin Exp Metastasis. 2013;30:529-40.
10. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell. 2006;9:425-34. (Pubitemid 43832190)
11. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7:11-20.
12. Koukourakis MI, Giatromanolaki A, Winter S, Leek R, Sivridis E, Harris AL. Lactate dehydrogenase 5 expression in squamous cell head and neck cancer relates to prognosis following radical or postoperative radiotherapy. Oncology Basel. 2009;77:285-92.
13. Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Trarbach T, Folprecht G, et al. Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy. Clin Cancer Res. 2011;17:4892-900.
14. Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov. 2011;10:767-77.
15. Yao F, Zhao T, Zhong C, Zhu J, Zhao H. LDHA is necessary for the tumorigenicity of esophageal squamous cell carcinoma. Tumour Biol. 2013;34:25-31.
16. Koukourakis MI, Giatromanolaki A, Sivridis E, Bougioukas G, Didilis V, Gatter KC, et al. Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer. 2003;89:877-85. (Pubitemid 37175811)
17. Kolev Y, Uetake H, Takagi Y, Sugihara K. Lactate dehydrogenase-5 (LDH-5) expression in human gastric cancer: association with hypoxia-inducible factor (HIF-1alpha) pathway, angiogenic factors production and poor prognosis. Ann Surg Oncol. 2008;15:2336-44.
18. Giatromanolaki A, Koukourakis MI, Pezzella F, Sivridis E, Turley H, Harris AL, et al. Lactate dehydrogenase 5 expression in non-Hodgkin B-cell lymphomas is associated with hypoxia regulated proteins. Leuk Lymphoma. 2008;49:2181-6.
19. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival end-points. Stat Med. 1998;17:2815-34. (Pubitemid 28562978)
20. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127:820-6. (Pubitemid 27465551)
21. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-58. (Pubitemid 34746062)
22. Giatromanolaki A, Koukourakis MI, Gatter KC, Harris AL, Sivridis E. BNIP3 expression in endometrial cancer relates to active hypoxia inducible factor 1alpha pathway and prognosis. J Clin Pathol. 2008;61:217-20. (Pubitemid 351218884)
23. Koukourakis MI, Giatromanolaki A, Sivridis E, Pitiakoudis M, Gatter KC, Harris AL. Beclin 1 over- and underexpression in colorectal cancer: distinct patterns relate to prognosis and tumour hypoxia. Br J Cancer. 2010;103:1209-14.
24. Kayser G, Kassem A, Sienel W, Schulte-Uentrop L, Mattern D, Aumann K, et al. Lactate-dehydrogenase 5 is overexpressed in non-small cell lung cancer and correlates with the expression of the transketolase-like protein 1. Diagn Pathol. 2010;5:22.
25. Giatromanolaki A, Koukourakis MI, Harris AL, Polychronidis A, Gatter KC, Sivridis E. Prognostic relevance of light chain 3 (LC3A) autophagy patterns in colorectal adenocarcinomas. J Clin Pathol. 2010;63:867-72.
26. Lu R, Jiang M, Chen Z, Xu X, Hu H, Zhao X, et al. Lactate dehydrogenase 5 expression in non-Hodgkin lymphoma is associated with the induced hypoxia regulated protein and poor prognosis. PLoS One. 2013;8:e74853.
27. Biswas S, Charlesworth PJ, Turner GD, Leek R, Thamboo PT, Campo L, et al. CD31 angiogenesis and combined expression of HIF-1α and HIF-2α are prognostic in primary clear-cell renal cell carcinoma (CC-RCC), but HIFα transcriptional products are not: implications for antiangiogenic trials and HIFα biomarker studies in primary CC-RCC. Carcinogenesis. 2012;33:1717-25.
28. Grimm M, Alexander D, Munz A, Hoffmann J, Reinert S. Increased LDH5 expression is associated with lymph node metastasis and outcome in oral squamous cell carcinoma. Clin Exp Metastasis. 2013;30:529-40.
29. Andersen S, Eilertsen M, Donnem T, Al-Shibli K, Al-Saad S, Busund LT, et al. Diverging prognostic impacts of hypoxicmarkers according to NSCLC histology. Lung Cancer J Iaslc. 2011;72:294-302.
30. Shim BY, Jung JH, Lee KM, Kim HJ, Hong SH, Kim SH, et al. Glucose transporter 1 (GLUT1) of anaerobic glycolysis as predictive and prognostic values in neoadjuvant chemoradiotherapy and laparoscopic surgery for locally advanced rectal cancer. Int J Color Dis. 2013;28:375-83.
31. Zhuang L, Scolyer RA, Murali R, McCarthy SW, Zhang XD, Thompson JF, et al. Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins. Mod Pathol. 2010;23:45-53.
32. Kim HS, Lee HE, Yang HK, Kim WH. High lactate dehydrogenase 5 expression correlates with high tumoral and stromal vascular endothelial growth factor expression in gastric cancer. Pathobiology. 2014;81:78-85.
33. Giatromanolaki A, Sivridis E, Gatter KC, Turley H, Harris AL, Koukourakis MI. Lactate dehydrogenase 5 (LDH-5) expression in endometrial cancer relates to the activated VEGF/VEGFR2(KDR) pathway and prognosis. Gynecol Oncol. 2006;103:912-8. (Pubitemid 44821314)
34. Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL. Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway - a report of the Tumour Angiogenesis Research Group. J Clin Oncol. 2006;24:4301-8. (Pubitemid 46630788)
35. Giatromanolaki A, Sivridis E, Bechrakis NE, Willerding G, St CG, Foerster MH, et al. Phosphorylated pVEGFR2/KDR receptor expression in uveal melanomas: relation with HIF2alpha and survival. Clin Exp Metastasis. 2012;29:11-7.
36. Sivridis E, Koukourakis MI, Mendrinos SE, Karpouzis A, Fiska A, Kouskoukis C, et al. Beclin-1 and LC3A expression in cutaneous malignant melanomas: a biphasic survival pattern for beclin-1. Melanoma Res. 2011;21:188-95.
37. Danner BC, Didilis VN, Wiemeyer S, Stojanovic T, Kitz J, Emmert A, et al. Long-term survival is linked to serum LDH and partly to tumour LDH-5 in NSCLC. Anticancer Res. 2010;30:1347-51.
38. Patil S, Figlin RA, Hutson TE, Michaelson MD, Negrier S, Kim ST, et al. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol. 2011;22:295-300.
39. Polee MB, Hop WC, Kok TC, Eskens FA, van der Burg ME, Splinter TA, et al. Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy. Br J Cancer. 2003;89:2045-50. (Pubitemid 38030901)
40. Koukourakis MI, Giatromanolaki A, Harris AL, Sivridis E. Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Res. 2006;66:632-7. (Pubitemid 43165922)
41. Katic KB. Comparison of glycolytic enzyme and isoenzyme activity in breast cancers and dysplasia. Med Pregl. 2012;65:200-5.
42. Koukourakis MI, Giatromanolaki A, Simopoulos C, Polychronidis A, Sivridis E. Lactate dehydrogenase 5 (LDH5) relates to up-regulated hypoxia inducible factor pathway and metastasis in colorectal cancer. Clin Exp Metastasis. 2005;22:25-30. (Pubitemid 41185858)
43. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell. 2006;9:425-34. (Pubitemid 43832190)
44. Wang ZY, Loo TY, Shen JG, Wang N, Wang DM, Yang DP, et al. LDH-A silencing suppresses breast cancer tumorigenicity through induction of oxidative stress mediated mitochondrial pathway apoptosis. Breast Cancer Res Treat. 2012;131:791-800.
45. Rong Y, Wu W, Ni X, Kuang T, Jin D, Wang D, et al. Lactate dehydrogenase a is overexpressed in pancreatic cancer and promotes the growth of pancreatic cancer cells. Tumour Biol. 2013;34:1523-30.
46. Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM, et al. Inhibition of lactate dehydrogenase a induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A. 2010;107:2037-42.
47. Granchi C, Paterni I, Rani R, Minutolo F. Small-molecule inhibitors of human LDH5. Futur Med Chem. 2013;5:1967-91.